|Slideshows|October 2, 2020

Best Practices for Motivational Pharmacotherapy Sessions

Author(s)Roberto Lewis-Fernández, MD, Angela A. Coombs, MD

These techniques may help promote self-efficacy and elicit patients’ commitment to resolve ambivalence about treatment.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Data Fails to Show Significant Change in Cognition and Function With Oral Semaglutide for Early Alzheimer Disease

ByJessica Walters

December 8th 2025

Favorable Profile Data On MK-2214 for Treatment of Alzheimer Disease

ByJessica Walters

December 5th 2025

What Happened to Psychopathology?

ByS. Nassir Ghaemi, MD, MPH,Mark L. Ruffalo, MSW, DPsa

December 5th 2025

Managing Treatment-Resistant Depression: Insights From David Medina, MD, FAPA

ByDavid Medina, MD, FAPA

December 2nd 2025

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State

ByGrace Thetford-Harvey, MD,Tessa Manning, MD

December 2nd 2025

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Best Practices for Motivational Pharmacotherapy Sessions

Newsletter

Related Content

Data Fails to Show Significant Change in Cognition and Function With Oral Semaglutide for Early Alzheimer Disease

Favorable Profile Data On MK-2214 for Treatment of Alzheimer Disease

What Happened to Psychopathology?

Managing Treatment-Resistant Depression: Insights From David Medina, MD, FAPA

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

NDA Submission: Olanzapine Extended-Release Injectable Suspension for Treatment of Schizophrenia

FDA Accepts NDA for TRN-257 for Treatment of Narcolepsy and Idiopathic Hypersomnia

Evenamide for Treatment-Resistant Schizophrenia: Initiation of ENIGMA-TRS 2 Phase 3 Clinical Study

In Memoriam and Transition: Carrie Soloway, MD

A Computer Expert's Advice On Protecting Chatbot Privacy